{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:17:52Z","timestamp":1790162272243,"version":"4.1.0"},"reference-count":139,"publisher":"European Respiratory Society (ERS)","issue":"4","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2014,10,9]]},"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:p>The United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. Before novel drugs can find their place in the battle against drug-resistant tuberculosis, linezolid has been compassionately used with success in the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis. This review largely discusses six novel drugs that have been evaluated in phase II and III clinical trials, with focus on the clinical evidence for efficacy and safety, potential drug interactions, and prospect for using multiple novel drugs in new regimens.<\/jats:p>","DOI":"10.1183\/09031936.00162314","type":"journal-article","created":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T15:50:35Z","timestamp":1417189835000},"page":"1119-1131","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":73,"title":["Novel drugs against tuberculosis: a clinician's perspective"],"prefix":"10.1183","volume":"45","author":[{"given":"Ioana Diana","family":"Olaru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"von Groote-Bidlingmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heyckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Wai","family":"Yew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok Chiu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2014,11,27]]},"reference":[{"key":"2024102023115578000_45.4.1119.1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1183\/09031936.00033010","article-title":"Treatment of tuberculosis update 2010","volume":"37","author":"Yew","year":"2010","journal-title":"Eur Respir J"},{"key":"2024102023115578000_45.4.1119.2","unstructured":"World Health Organization. Treatment of Tuberculosis Guidelines. 4th Edn. Geneva, World Health Organization, 2010."},{"key":"2024102023115578000_45.4.1119.3","first-page":"253","article-title":"Treatment of tuberculosis","volume":"33","author":"Iseman","year":"1988","journal-title":"Adv Intern Med"},{"key":"2024102023115578000_45.4.1119.4","first-page":"790","article-title":"American Thoracic Society, Center for Disease Control. Treatment of tuberculosis and other mycobacterial disease","volume":"127","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"2024102023115578000_45.4.1119.5","first-page":"91","article-title":"Treatment of tuberculosis. The Mitchell Lecture 1979","volume":"14","author":"Mitchison","year":"1980","journal-title":"J Roy Coll Phys London"},{"key":"2024102023115578000_45.4.1119.6","first-page":"325","article-title":"Short-course chemotherapy for pulmonary tuberculosis","volume":"111","author":"Fox","year":"1975","journal-title":"Am Rev Respir Dis"},{"key":"2024102023115578000_45.4.1119.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91426-9"},{"key":"2024102023115578000_45.4.1119.8","first-page":"1102","article-title":"Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association","volume":"2","year":"1976","journal-title":"Lancet"},{"key":"2024102023115578000_45.4.1119.9","first-page":"28","article-title":"Madras study of short-course chemotherapy in pulmonary tuberculosis","volume":"54","author":"Tripathy","year":"1979","journal-title":"Bull Int Union Tuberc Lung Dis"},{"key":"2024102023115578000_45.4.1119.10","first-page":"1182","article-title":"Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic Association (third report)","volume":"1","author":"Somner","year":"1980","journal-title":"Lancet"},{"key":"2024102023115578000_45.4.1119.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-397"},{"key":"2024102023115578000_45.4.1119.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0363PP"},{"key":"2024102023115578000_45.4.1119.13","unstructured":"World Health Organization. Management of MDR-TB: a Field Guide: a Companion Document to Guidelines for Programmatic Management of Drug-resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI). Geneva, World Health Organization, 2009."},{"key":"2024102023115578000_45.4.1119.14","unstructured":"World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Emergency Update 2008. Geneva, World Health Organization, 2008."},{"key":"2024102023115578000_45.4.1119.15","unstructured":"World Health Organization. Global Tuberculosis Report 2012. Geneva, World Health Organization, 2012."},{"key":"2024102023115578000_45.4.1119.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00134712"},{"key":"2024102023115578000_45.4.1119.17","doi-asserted-by":"crossref","first-page":"20733","DOI":"10.2807\/1560-7917.ES2014.19.10.20733","article-title":"Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012","volume":"19","author":"van der Werf","year":"2014","journal-title":"Euro Surveill"},{"key":"2024102023115578000_45.4.1119.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2012.05.008"},{"key":"2024102023115578000_45.4.1119.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007954"},{"key":"2024102023115578000_45.4.1119.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2024102023115578000_45.4.1119.21","unstructured":"World Health Organization. Definitions and Reporting Framework for Tuberculosis \u2013 2013 Revision. Geneva, World Health Organization, 2013."},{"key":"2024102023115578000_45.4.1119.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00124614"},{"key":"2024102023115578000_45.4.1119.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201304-0697ED"},{"key":"2024102023115578000_45.4.1119.24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.4.1476"},{"key":"2024102023115578000_45.4.1119.25","doi-asserted-by":"publisher","DOI":"10.1086\/653115"},{"key":"2024102023115578000_45.4.1119.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00009509"},{"key":"2024102023115578000_45.4.1119.27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks078"},{"key":"2024102023115578000_45.4.1119.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00388-13"},{"key":"2024102023115578000_45.4.1119.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00188313"},{"key":"2024102023115578000_45.4.1119.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4582.769"},{"key":"2024102023115578000_45.4.1119.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4787.735"},{"key":"2024102023115578000_45.4.1119.32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu572"},{"key":"2024102023115578000_45.4.1119.33","doi-asserted-by":"publisher","DOI":"10.1126\/science.339.6116.130"},{"key":"2024102023115578000_45.4.1119.34","unstructured":"European Medicines Agency, Press Release. European Medicines Agency Recommends Approval of a New Medicine for Multidrug-resistant Tuberculosis. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/12\/news_detail_001999.jsp&mid=WC0b01ac058004d5c1 December 20, 2013. Date last accessed: August 29, 2014."},{"key":"2024102023115578000_45.4.1119.35","unstructured":"Johnson and Johnson, Press Release. SIRTURO\u00ae (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-drug Resistant Tuberculosis. www.investor.jnj.com\/releasedetail.cfm?ReleaseID=831021 March 6, 2014. Date last accessed: July 24, 2014."},{"key":"2024102023115578000_45.4.1119.36","unstructured":"US Food and Drug Administration. FDA News Release on Bedaquiline Approval. www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm333695.htm December 31, 2012. Date last accessed: August 29, 2014."},{"key":"2024102023115578000_45.4.1119.37","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"2024102023115578000_45.4.1119.38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M803899200"},{"key":"2024102023115578000_45.4.1119.39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00037-14"},{"key":"2024102023115578000_45.4.1119.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102135"},{"key":"2024102023115578000_45.4.1119.41","first-page":"1","article-title":"Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"2024102023115578000_45.4.1119.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"2024102023115578000_45.4.1119.43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06126-11"},{"key":"2024102023115578000_45.4.1119.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"2024102023115578000_45.4.1119.45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05293-11"},{"key":"2024102023115578000_45.4.1119.46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00384-12"},{"key":"2024102023115578000_45.4.1119.47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"2024102023115578000_45.4.1119.48","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932050-00001"},{"key":"2024102023115578000_45.4.1119.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"2024102023115578000_45.4.1119.50","unstructured":"Dannemann BR , Bakare N , De Marez T , et al . Corrected QT Interval (QTcF) Prolongation in a Phase 2 Open-label Trial of TMC207 Plus Background Regimen (BR) as Treatment for MDR-TB: Effect of Co-administration with Clofazimine (CFZ). 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy: Abstract A1259. www.icaaconline.com\/php\/icaac2013abstracts\/data\/papers\/2012\/A\/2012_A-1259.htm"},{"key":"2024102023115578000_45.4.1119.51","unstructured":"European Medicines Agency. Summary of Opinion. Delamanid. www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002552\/WC500155458.pdf November 21, 2013. Date last accessed: July 24, 2014."},{"key":"2024102023115578000_45.4.1119.52","unstructured":"European Medicines Agency. Deltyba Product Infomation. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002552\/WC500166232.pdf Date last accessed: July 24, 2014."},{"key":"2024102023115578000_45.4.1119.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"2024102023115578000_45.4.1119.54","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00125812"},{"key":"2024102023115578000_45.4.1119.55","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164571"},{"key":"2024102023115578000_45.4.1119.56","doi-asserted-by":"crossref","unstructured":"Manjunatha U , Boshoff HI , Barry CE . The mechanism of action of PA-824 novel insights from transcriptional profiling. Commun Integr Biol 2009; 215\u2013218.","DOI":"10.4161\/cib.2.3.7926"},{"key":"2024102023115578000_45.4.1119.57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-13-218"},{"key":"2024102023115578000_45.4.1119.58","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"2024102023115578000_45.4.1119.59","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00106-09"},{"key":"2024102023115578000_45.4.1119.60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2294-2301.2005"},{"key":"2024102023115578000_45.4.1119.61","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2289-2293.2005"},{"key":"2024102023115578000_45.4.1119.62","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05500-11"},{"key":"2024102023115578000_45.4.1119.63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508392103"},{"key":"2024102023115578000_45.4.1119.64","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02693-13"},{"key":"2024102023115578000_45.4.1119.65","first-page":"69","article-title":"Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis","volume":"12","author":"Hu","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023115578000_45.4.1119.66","unstructured":"Global Alliancefor TB . Drug Development. Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-resistant Pulmonary Tuberculosis (TB) 2013. http\/\/clinicaltrials.gov\/ct2\/show\/NCT01498419 Date last updated: March 12, 2013."},{"key":"2024102023115578000_45.4.1119.67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00112-09"},{"key":"2024102023115578000_45.4.1119.68","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-09"},{"key":"2024102023115578000_45.4.1119.69","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06125-11"},{"key":"2024102023115578000_45.4.1119.70","unstructured":"Effect of PA-824 and of PA-824 Plus Moxifloxacinon the QTc Interval in Healthy Volunteers. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01674218?term=NCT01674218&rank=1 Date last updated: February 14, 2013. Date last accessed: April 8, 2014."},{"key":"2024102023115578000_45.4.1119.71","doi-asserted-by":"publisher","DOI":"10.1021\/jm950956y"},{"key":"2024102023115578000_45.4.1119.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.03.002"},{"key":"2024102023115578000_45.4.1119.73","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01179-10"},{"key":"2024102023115578000_45.4.1119.74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094462"},{"key":"2024102023115578000_45.4.1119.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"2024102023115578000_45.4.1119.76","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01903-13"},{"key":"2024102023115578000_45.4.1119.77","unstructured":"Reele S , Xiao AJ , Das S , et al . 14 Day Multiple Ascending Dose Study with AZD5847 Is Well Tolerated at Predicted Exposure for Treatment of Tuberculosis (TB). 51st Interscience Conference on Antimicrobial Agents and Chemotherapy: Abstract A11735. http:\/\/www.abstractsonline.com\/plan\/ViewAbstract.aspx?mID=2789&sKey=0b498641-f10a-4936-b80c-d274ffe4b143&cKey=2271e63a-2cdc-4956-b7b0-6f7dc642b346&mKey=0c918954-d607-46a7-8073-44f4b537a439"},{"key":"2024102023115578000_45.4.1119.78","unstructured":"Phase 2a EBA Trial of AZD5847. http:\/\/clinicaltrials.gov\/show\/NCT01516203 Date last updated: April 16, 2014. Date last accessed: June 29, 2014."},{"key":"2024102023115578000_45.4.1119.79","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05708-11"},{"key":"2024102023115578000_45.4.1119.80","unstructured":"The HIV i-Base\/Treatment Action Group . 2013 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development. Benzacar A, Horn T, Morgan S, eds. London, HIV i-Base, 2013."},{"key":"2024102023115578000_45.4.1119.81","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00191-13"},{"key":"2024102023115578000_45.4.1119.82","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.124519"},{"key":"2024102023115578000_45.4.1119.83","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182410503"},{"key":"2024102023115578000_45.4.1119.84","unstructured":"Van Heeswijk R , Vandevoorde A , Meyvisch P , et al . The Effect of Nevirapine on the Pharmacokinetics of TMC207, an Investigational Antimycobacterial Agent, in HIV-1-infected Subjects. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Abstract MOPE172. http:\/\/pag.ias2011.org\/abstracts.aspx?aid=1350 ."},{"key":"2024102023115578000_45.4.1119.85","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1208719"},{"key":"2024102023115578000_45.4.1119.86","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874083"},{"key":"2024102023115578000_45.4.1119.87","unstructured":"Petersen C , Paccaly A , Kim J , et al . Delamanid, a New Drug for Multi-drug Resistant Tuberculosis (MDR-TB), and Efavirenz Do Not Show Clinically Relevant Drug Interactions in Healthy Subjects. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy: Abstract A-1255. http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=a96a704b-ee24-44df-8955-f1688acf7663&cKey=0be05c32-0d75-4e82-9117-0b465a0e1daf&mKey={6B114A1D-85A4-4054-A83B-04D8B9B8749F}"},{"key":"2024102023115578000_45.4.1119.88","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2054"},{"key":"2024102023115578000_45.4.1119.89","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.56"},{"key":"2024102023115578000_45.4.1119.90","first-page":"663","article-title":"New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades","volume":"14","author":"Spigelman","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023115578000_45.4.1119.91","unstructured":"World Health Organization. Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva, World Health Organization, 2008."},{"key":"2024102023115578000_45.4.1119.92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60734-X"},{"key":"2024102023115578000_45.4.1119.93","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00630-11"},{"key":"2024102023115578000_45.4.1119.94","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0266"},{"key":"2024102023115578000_45.4.1119.95","unstructured":"Global Alliancefor TB . Drug Development. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01691534?term=NCT01691534&rank=1 Date last updated: April 11, 2013."},{"key":"2024102023115578000_45.4.1119.96","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-09"},{"key":"2024102023115578000_45.4.1119.97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030479"},{"key":"2024102023115578000_45.4.1119.98","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr589"},{"key":"2024102023115578000_45.4.1119.99","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00686-08"},{"key":"2024102023115578000_45.4.1119.100","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00898-06"},{"key":"2024102023115578000_45.4.1119.101","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0708ED"},{"key":"2024102023115578000_45.4.1119.102","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.870884"},{"key":"2024102023115578000_45.4.1119.103","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis041"},{"key":"2024102023115578000_45.4.1119.104","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00122313"},{"key":"2024102023115578000_45.4.1119.105","unstructured":"Deltyba: New Antibacterial for Multidrug-resistant Tuberculosis. http:\/\/www.mims.co.uk\/deltyba-new-antibacterial-multidrug-resistant-tuberculosis\/infections-and-infestations\/article\/1298056. Date last updated: June 16, 2014. Date last accessed: July 24, 2014."},{"key":"2024102023115578000_45.4.1119.106","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00113713"},{"key":"2024102023115578000_45.4.1119.107","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.14-3-279"},{"key":"2024102023115578000_45.4.1119.108","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2012.07.009"},{"key":"2024102023115578000_45.4.1119.109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081634"},{"key":"2024102023115578000_45.4.1119.110","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00277-13"},{"key":"2024102023115578000_45.4.1119.111","first-page":"89","article-title":"Role of pharmacogenomics in the treatment of tuberculosis: a review","volume":"5","author":"Ramachandran","year":"2012","journal-title":"Pharmacogenomics Pers Med"},{"key":"2024102023115578000_45.4.1119.112","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2010.08.009"},{"key":"2024102023115578000_45.4.1119.113","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1950.04040020216002"},{"key":"2024102023115578000_45.4.1119.114","doi-asserted-by":"publisher","DOI":"10.1086\/317524"},{"key":"2024102023115578000_45.4.1119.115","doi-asserted-by":"publisher","DOI":"10.1211\/0022357055092"},{"key":"2024102023115578000_45.4.1119.116","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02346-12"},{"key":"2024102023115578000_45.4.1119.117","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01897-12"},{"key":"2024102023115578000_45.4.1119.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.10.044"},{"key":"2024102023115578000_45.4.1119.119","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics4030385"},{"key":"2024102023115578000_45.4.1119.120","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2012.721144"},{"key":"2024102023115578000_45.4.1119.121","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01471-09"},{"key":"2024102023115578000_45.4.1119.122","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01389-08"},{"key":"2024102023115578000_45.4.1119.123","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.176"},{"key":"2024102023115578000_45.4.1119.124","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e32835f27f8"},{"key":"2024102023115578000_45.4.1119.125","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12031"},{"key":"2024102023115578000_45.4.1119.126","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.1"},{"key":"2024102023115578000_45.4.1119.127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2011.05.002"},{"key":"2024102023115578000_45.4.1119.128","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis197"},{"key":"2024102023115578000_45.4.1119.129","doi-asserted-by":"publisher","DOI":"10.2741\/1292"},{"key":"2024102023115578000_45.4.1119.130","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283350f1b"},{"key":"2024102023115578000_45.4.1119.131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023826"},{"key":"2024102023115578000_45.4.1119.132","doi-asserted-by":"publisher","DOI":"10.4161\/hv.25280"},{"key":"2024102023115578000_45.4.1119.133","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.110"},{"key":"2024102023115578000_45.4.1119.134","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.96"},{"key":"2024102023115578000_45.4.1119.135","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.59"},{"key":"2024102023115578000_45.4.1119.136","doi-asserted-by":"crossref","unstructured":"Ahsan MJ , Garg SK , Vashishtha B , et al. Tuberculosis vaccines: hopes and hurdles. Infect Disord Drug Targets 2013; 13;3: 318\u2013321.","DOI":"10.2174\/1871526513666131201125513"},{"key":"2024102023115578000_45.4.1119.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2012.12.002"},{"key":"2024102023115578000_45.4.1119.138","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6111-1_14"},{"key":"2024102023115578000_45.4.1119.139","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70033-5"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00162314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:54:38Z","timestamp":1740380078000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00162314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,27]]},"references-count":139,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,31]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1183\/09031936.00162314"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00162314","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,27]]}}}